It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Mechanisms of tumor immune escape are quite diverse and require specific approaches for their exploration in syngeneic tumor models. In several human malignancies, galectin-9 (gal-9) is suspected to contribute to the immune escape. However, in contrast with what has been done for the infiltrating cells, the contribution of gal-9 produced by malignant cells has never been demonstrated in an animal model. Therefore, we derived isogenic clones—either positive or negative for gal-9—from the MB49 murine bladder carcinoma cell line. A progressive and consistent reduction of tumor growth was observed when gal-9-KO cells were subjected to serial transplantations into syngeneic mice. In contrast, tumor growth was unaffected during parallel serial transplantations into nude mice, thus linking tumor inhibition to the enhancement of the immune response against gal-9-KO tumors. This stronger immune response was at least in part explained by changing patterns of response to interferon-γ. One consistent change was a more abundant production of CXCL10, a major inflammatory factor whose production is often induced by interferon-γ. Overall, these observations demonstrate for the first time that serial transplantation into syngeneic mice can be a valuable experimental approach for the exploration of novel mechanisms of tumor immune escape.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Gustave Roussy and Université Paris-Saclay, CNRS, UMR 9018, Villejuif, France (GRID:grid.14925.3b) (ISNI:0000 0001 2284 9388)
2 Gustave Roussy, Inserm, U1170, Villejuif, France (GRID:grid.14925.3b) (ISNI:0000 0001 2284 9388)
3 Gustave Roussy, Plateforme de pathologie expérimentale et translationnelle, UMS AMMICA, Villejuif, France (GRID:grid.14925.3b) (ISNI:0000 0001 2284 9388)
4 Gustave Roussy, Plateforme de Bioinformatique, UMS AMMICA, Villejuif, France (GRID:grid.14925.3b) (ISNI:0000 0001 2284 9388)
5 Pépinière Paris Santé Cochin, HiFiBiO Therapeutics, Paris, France (GRID:grid.14925.3b)